ALEMBIC Revenue vs. Cash and Equivalents

<div class='circular--portrait' style='background:#FF01C9;color: #FFF8DC;font-size:3em;padding-top: 38px;;'>ALE</div>
The Drivers Module shows relationships between ALEMBIC's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of ALEMBIC LTD over time as well as its relative position and ranking within its peers. Check out Trending Equities.

Search Current Fundamental Trends

 
Refresh

ALEMBIC LTD Cash and Equivalents vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ALEMBIC's current stock value. Our valuation model uses many indicators to compare ALEMBIC value to that of its competitors to determine the firm's financial worth.
ALEMBIC LTD is the top company in revenue category among related companies. It is number one stock in cash and equivalents category among related companies creating about  0.36  of Cash and Equivalents per Revenue. The ratio of Revenue to Cash and Equivalents for ALEMBIC LTD is roughly  2.82 
ALEMBIC LTD is the top company in revenue category among related companies. Market size based on revenue of Drug Manufacturers - Specialty & Generic industry is presently estimated at about 2.56 Billion. ALEMBIC totals roughly 1.28 Billion in revenue claiming about 50% of equities under Drug Manufacturers - Specialty & Generic industry.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
ALEMBIC 
Revenue 
 = 
Money Received 
Discounts and Returns 
=
1.28 B
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
ALEMBIC 
Cash 
 = 
Bank Deposits 
+  
Liquidities 
=
454.7 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

ALEMBIC Cash and Equivalents Comparison

ALEMBIC Fundamental Comparison

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page